INVA Stock Analysis: Innoviva | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 1.616m USD | 12M Return: 17.7% | Charts, Fundamentals & Technical Analysis

Respiratory Inhalers, Critical Care, Antibiotics, Infectious Disease
Total Rating 51
Safety 75
Buy Signal 0.02
Biotechnology
Industry Rotation: +30.9
Market Cap: 1.62B
Avg Turnover: 18.0M
Risk 3d forecast
Volatility23.6%
VaR 5th Pctl3.98%
VaR vs Median2.55%
Reward TTM
Sharpe Ratio0.55
Rel. Str. IBD46.4
Rel. Str. Peer Group43.8
Character TTM
Beta0.016
Beta Downside0.106
Hurst Exponent0.557
Drawdowns 3y
Max DD23.53%
CAGR/Max DD0.91
CAGR/Mean DD3.11
EPS (Earnings per Share) EPS (Earnings per Share) of INVA over the last years for every Quarter: "2021-06": 0.9, "2021-09": 0.9, "2021-12": 0.14, "2022-03": 0.44, "2022-06": 0.62, "2022-09": 0.54, "2022-12": -0.98, "2023-03": 0.42, "2023-06": 0.02, "2023-09": 0.18, "2023-12": 0.76, "2024-03": 0.46, "2024-06": -0.55, "2024-09": 0.12, "2024-12": 0.26, "2025-03": -0.7429, "2025-06": 0.77, "2025-09": 1.08, "2025-12": 1.944, "2026-03": 0.47,
Last SUE: 0.05
Qual. Beats: 0
Revenue Revenue of INVA over the last years for every Quarter: 2021-06: 100.806, 2021-09: 97.862, 2021-12: 107.68, 2022-03: 90.059, 2022-06: 108.22, 2022-09: 67.257, 2022-12: 65.803, 2023-03: 76.372, 2023-06: 80.992, 2023-09: 67.259, 2023-12: 85.84, 2024-03: 77.499, 2024-06: 103.354, 2024-09: 89.508, 2024-12: 91.806, 2025-03: 88.632, 2025-06: 100.283, 2025-09: 107.8, 2025-12: 118.045, 2026-03: 97.994,
Rev. CAGR: 15.26%
Rev. Trend: 98.7%
Last SUE: -0.13
Qual. Beats: 0

Warnings

Earnings Expected To Drop (P/E To P/E Forward)
Strong Share Dilution
Below Avwap Earnings

Tailwinds

No distinct edge detected

Seasonality 10.5 years of data

Jan -0.5% 43
Feb -0.4% 13
Mar -1.1% 29
Apr -1.2% 14
May +1.5% 15
Jun +2.2% 27
Jul +0.1% 8
Aug +0.0% 8
Sep -2.3% 20
Oct -0.7% 21
Nov +3.5% 6
Dec +3.8% 6

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: INVA Innoviva

Innoviva, Inc. (NASDAQ: INVA) is a US-headquartered biopharmaceutical company operating domestically and internationally, generating revenue through a hybrid model that combines royalty streams from partnered respiratory products with direct commercialization of specialty hospital antibiotics. Its royalty portfolio centers on GlaxoSmithKline-partnered therapies RELVAR/BREO ELLIPTA and ANORO ELLIPTA, both once-daily inhaled treatments for chronic obstructive pulmonary disease (COPD) and asthma. The company also markets a portfolio of hospital-focused anti-infectives, including GIAPREZA (septic shock), XACDURO (Acinetobacter pneumonia), XERAVA (intra-abdominal infections), ZEVTERA (a cephalosporin antibiotic), and NUZOLVENCE (gonorrhea). Innoviva is additionally advancing a pipeline of bacteriophage-based therapies targeting infectious and other serious diseases and maintains a strategic partnership with activist investor Sarissa Capital Management. Originally incorporated in 1996 as Theravance, Inc., the company rebranded to Innoviva in January 2016 and remains based in Burlingame, California, operating within the Health Care sector under the Pharmaceuticals sub-industry classification.

Headlines to Watch Out For
  • GSK royalty revenue from RELVAR and ANORO faces generic erosion
  • Hospital therapeutics portfolio expands with XERAVA and XACDURO launches
  • Sarissa partnership drives aggressive buybacks and special dividends
Piotroski VR-10 (Strict) 3.0
Net Income: 504.3m TTM > 0 and > 6% of Revenue
FCF/TA: 0.10 > 0.02 and ΔFCF/TA -5.78 > 1.0
NWC/Revenue: 173.6% < 20% (prev 93.03%; Δ 80.52% < -1%)
CFO/TA 0.10 > 3% & CFO 183.6m > Net Income 504.3m
Net Debt (-269.2m) to EBITDA (639.9m): -0.42 < 3
Current Ratio: 21.13 > 1.5 & < 3
Outstanding Shares: last quarter (84.8m) vs 12m ago 35.31% < -2%
Gross Margin: 76.20% > 18% (prev 88.11%; Δ -11.91% > 0.5%)
Asset Turnover: 27.44% > 50% (prev 29.76%; Δ -2.32% > 0%)
Interest Coverage Ratio: 34.81 > 6 (EBIT TTM 606.6m / Interest Expense TTM 17.4m)
Altman Z'' 8.92
A: 0.40 (Total Current Assets 772.6m - Total Current Liabilities 36.6m) / Total Assets 1.84b
B: 0.25 (Retained Earnings 456.0m / Total Assets 1.84b)
C: 0.39 (EBIT TTM 606.6m / Avg Total Assets 1.55b)
D: 2.71 (Book Value of Equity 1.34b / Total Liabilities 494.9m)
Altman-Z'' = 8.92 = AAA
Beneish M -2.69
DSRI: 1.05 (Receivables 92.6m/77.9m, Revenue 424.1m/373.3m)
GMI: 1.16 (GM 88.11% / 76.20%)
AQI: 1.07 (AQ_t 0.57 / AQ_t-1 0.53)
SGI: 1.14 (Revenue 424.1m / 373.3m)
TATA: 0.17 (NI 504.3m - CFO 183.6m) / TA 1.84b)
Beneish M = -2.69 (Cap -4..+1) = A
What is the price of INVA shares?

As of July 08, 2026, the stock is trading at USD 22.25 with a total of 513,399 shares traded. Over the past week, the price has changed by -3.85%, over one month by -0.36%, over three months by -4.42% and over the past year by +17.66%.

Current recommended Stop Loss: 21.30 (which is 4.3% or 1.4 ATR below the current price).

Is INVA a buy, sell or hold?

Innoviva has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy INVA.

  • StrongBuy: 0
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the INVA price?
Analysts Target Price 35.5 59.6%
Innoviva (INVA) - Fundamental Data Overview as of 03 July 2026
Market Cap USD = 1.62b (1.62b USD * 1.0 USD.USD)
P/E Trailing = 3.4984
P/E Forward = 11.5875
P/S = 3.8423
P/B = 1.2499
P/EG = 0.3312
Revenue TTM = 424.1m USD
EBIT TTM = 606.6m USD
EBITDA TTM = 639.9m USD
Long Term Debt = 258.1m USD (from longTermDebt, last quarter)
Short Term Debt = 5.34m USD (from shortTermDebt, last quarter)
Debt = 342.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 11.3m
Net Debt = -269.2m USD (calculated: Debt 342.7m - CCE 611.9m)
Enterprise Value = 1.35b USD (1.62b + Debt 342.7m - CCE 611.9m)
Interest Coverage Ratio = 34.81 (Ebit TTM 606.6m / Interest Expense TTM 17.4m)
EV/FCF = 7.45x (Enterprise Value 1.35b / FCF TTM 180.9m)
FCF Yield = 13.42% (FCF TTM 180.9m / Enterprise Value 1.35b)
FCF Margin = 42.64% (FCF TTM 180.9m / Revenue TTM 424.1m)
Net Margin = 118.9% (Net Income TTM 504.3m / Revenue TTM 424.1m)
Gross Margin = 76.20% ((Revenue TTM 424.1m - Cost of Revenue TTM 101.0m) / Revenue TTM)
Gross Margin QoQ = 77.39% (prev 64.05%)
Tobins Q-Ratio = 0.73 (Enterprise Value 1.35b / Total Assets 1.84b)
Interest Expense / Debt = 5.08% (Interest Expense 17.4m / Debt 342.7m)
Taxrate = 15.94% (95.7m / 600.0m)
NOPAT = 509.8m (EBIT 606.6m * (1 - 15.94%))
Current Ratio = 21.13 (Total Current Assets 772.6m / Total Current Liabilities 36.6m)
Debt / Equity = 0.26 (Debt 342.7m / totalStockholderEquity, last quarter 1.34b)
Debt / EBITDA = -0.42 (Net Debt -269.2m / EBITDA 639.9m)
Debt / FCF = -1.49 (Net Debt -269.2m / FCF TTM 180.9m)
Total Stockholder Equity = 1.06b (last 4 quarters mean from totalStockholderEquity)
RoA = 32.63% (Net Income 504.3m / Total Assets 1.84b)
RoE = 47.59% (Net Income TTM 504.3m / Total Stockholder Equity 1.06b)
RoCE = 46.02% (EBIT 606.6m / Capital Employed (Equity 1.06b + L.T.Debt 258.1m))
RoIC = 28.58% (NOPAT 509.8m / Invested Capital 1.78b)
WACC = 5.73% (E(1.62b)/V(1.96b) * Re(6.04%) + D(342.7m)/V(1.96b) * Rd(5.08%) * (1-Tc(0.16)))
Discount Rate = 6.04% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 24.44 | Cagr: -0.08%
[DCF] Terminal Value 74.32% ; FCFF base≈186.9m ; Y1≈175.5m ; Y5≈162.6m
[DCF] Fair Price = 38.43 (EV 2.57b - Net Debt -269.2m = Equity 2.84b / Shares 73.8m; r=8.35% [WACC [floored]]; 5y FCF grow -7.72% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.05 | # QB: 0
Revenue Correlation: 98.70 | Revenue CAGR: 15.26% | SUE: -0.13 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.50 | Chg30d=+0.00% | Revisions=+0% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.46 | Chg30d=+0.00% | Revisions=-25% | Analysts=1
EPS current Year (2026-12-31): EPS=1.91 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+1.9% | GrowthRev=+7.1%
EPS next Year (2027-12-31): EPS=2.21 | Chg30d=-3.28% | Revisions=-40% | GrowthEPS=+15.7% | GrowthRev=+10.3%